Acepodia
PublicAcepodia is now publicly traded
The data on this page reflects Acepodia's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
Jun 6, 2023
Total Funding Raised
$256M
Company Overview
Acepodia (ROCO: 6976) is a biotechnology company focused on developing innovative, first-in-class cell therapies for cancer using its Antibody-Cell Conjugation platform technology to ensure broad accessibility for patients.
Sector
Biotech
AI Layer
Non-AI
Keywords
Acepodia Comparables
Compare Acepodia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Indapta Therapeutics | 80% | |
| Cartherics | 77% | |
| ONK Therapeutics | 76% |
Acepodia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 6, 2023 | ||||
| Series C | Dec 2, 2021 | ||||
| Series B | Mar 16, 2021 |
Acepodia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Maxpro Ventures | Series C |
| CDIB Capital Healthcare | Series C |
| CDIB Capital International | Series B |
| E.SUN Venture Capital | Series C, Series B |
| 8VC | Series C, Series B |
| DEFTA Partners | Series C, Series B |
| Shanghai Becky Biotechnology | Series B |
Acepodia Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access